Rvnc should own CD bc of the value proposition to all involved patients payers etc. if RVNC could have spun out a therapeutics company amd rebranded the drug they would be charging much higher prices in therapeutics and still would be cheaper for payers bc of the savings in doctor visits etc. episodic migraine is higher risk but they probably can build some IP around it so bigger upside for sure. (I think abbv has chronic migraine only in label)
News 
Market Data 
Discover 
